RU2726416C2 - Антифиброгенные соединения, способы и их применение - Google Patents

Антифиброгенные соединения, способы и их применение Download PDF

Info

Publication number
RU2726416C2
RU2726416C2 RU2015156196A RU2015156196A RU2726416C2 RU 2726416 C2 RU2726416 C2 RU 2726416C2 RU 2015156196 A RU2015156196 A RU 2015156196A RU 2015156196 A RU2015156196 A RU 2015156196A RU 2726416 C2 RU2726416 C2 RU 2726416C2
Authority
RU
Russia
Prior art keywords
fibrosis
kynurenine
compound
mmp
expression
Prior art date
Application number
RU2015156196A
Other languages
English (en)
Russian (ru)
Other versions
RU2015156196A3 (enExample
RU2015156196A (ru
Inventor
Азиз ГАХАРИ
Юньюань ЛИ
Рухангиз Т. КИЛАНИ
Райан ХАРТВЕЛЛ
Original Assignee
Ти Юниверсити Оф Бритиш Коламбиа
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ти Юниверсити Оф Бритиш Коламбиа filed Critical Ти Юниверсити Оф Бритиш Коламбиа
Publication of RU2015156196A publication Critical patent/RU2015156196A/ru
Publication of RU2015156196A3 publication Critical patent/RU2015156196A3/ru
Application granted granted Critical
Publication of RU2726416C2 publication Critical patent/RU2726416C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2015156196A 2013-06-05 2014-06-04 Антифиброгенные соединения, способы и их применение RU2726416C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361831404P 2013-06-05 2013-06-05
US61/831,404 2013-06-05
PCT/CA2014/000484 WO2014194407A1 (en) 2013-06-05 2014-06-04 Anti-fibrogenic compounds, methods and uses thereof

Publications (3)

Publication Number Publication Date
RU2015156196A RU2015156196A (ru) 2017-07-14
RU2015156196A3 RU2015156196A3 (enExample) 2018-05-24
RU2726416C2 true RU2726416C2 (ru) 2020-07-14

Family

ID=52007349

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015156196A RU2726416C2 (ru) 2013-06-05 2014-06-04 Антифиброгенные соединения, способы и их применение

Country Status (14)

Country Link
US (1) US9737523B2 (enExample)
EP (1) EP3003298B1 (enExample)
JP (1) JP6473938B2 (enExample)
KR (1) KR102294405B1 (enExample)
AU (1) AU2014277568B2 (enExample)
CA (1) CA2914261C (enExample)
DK (1) DK3003298T3 (enExample)
ES (1) ES2978920T3 (enExample)
PH (1) PH12015502717B1 (enExample)
PL (1) PL3003298T3 (enExample)
RU (1) RU2726416C2 (enExample)
SG (1) SG11201510003VA (enExample)
WO (1) WO2014194407A1 (enExample)
ZA (1) ZA201600015B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018144461A1 (en) 2017-01-31 2018-08-09 The Board Of Regents Of The University Of Oklahoma Animal wound model and methods of use
CN112168822B (zh) * 2020-09-27 2022-11-08 集美大学 犬尿酸在改善高脂饮食致血脂异常、肥胖、肠道菌群混乱中的用途
JP2024517463A (ja) * 2021-05-04 2024-04-22 ソヴィダ ソリューションズ リミテッド ニコチンアミドアデニンジヌクレオチド（ｎａｄ）組成物、それらの製造方法、及びそれらの使用方法
KR20240004954A (ko) * 2021-05-07 2024-01-11 바치바이오메드 인크. 소분자 화합물을 사용하여 여드름-후 위축성 흉터의 외관을 개선하는 방법 (methods of using a small molecule chemical compound to reduce the appearance of post-acne atrophic scarring)
EP4572737A1 (en) * 2022-09-14 2025-06-25 Birchbiomed Inc. Methods of using a small molecule chemical compound to reduce the appearance of rhytids and wrinkles
US20240189279A1 (en) * 2022-12-11 2024-06-13 The Texas A&M University System Immunomodulatory compositions and methods of use thereof
CN119055650A (zh) * 2024-09-06 2024-12-03 上海市东方医院（同济大学附属东方医院） 犬尿喹啉酸在治疗慢性肝硬化中的应用
PL450606A1 (pl) 2024-12-16 2026-06-22 Uniwersytet Łódzki Zastosowanie tryptofanu lub jego metabolitów ze szlaku kynureninowego w profilaktyce i leczeniu dermatofitoz oraz kompozycja farmaceutyczna do stosowania zewnętrznego

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2251411C2 (ru) * 1999-07-01 2005-05-10 Фудзисава Фармасьютикал Ко., Лтд. Стабилизированная фармацевтическая композиция в лиофилизированной форме
US20080161353A1 (en) * 2002-07-16 2008-07-03 Kevin Jeffrey Barnham 8-Hydroxy quinoline derivatives
WO2008087461A2 (en) * 2007-01-17 2008-07-24 Szegedi Tudományegyetem Use of kynurenic acid and derivatives thereof in the treatment of conditions of the gastrointestinal tract accompanied by hypermotility and inflammation or gout or multiple sclerosis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1369114A1 (en) 2002-06-07 2003-12-10 Peter Priv. Doz. Dr. Terness Use of tryptophan metabolites as pharmaceutical agents
WO2006053390A1 (en) * 2004-11-17 2006-05-26 Angiogen Pharmaceuticals Pty. Ltd. A method of modulating b cell functioning
KR20150021071A (ko) * 2012-06-15 2015-02-27 코나리스 리써치 인스티튜트 아게 니코틴산 및/또는 니코틴아미드 및/또는 트립토판을 포함하는 장내 세균총에 유익한 효능을 가진 약학 조성물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2251411C2 (ru) * 1999-07-01 2005-05-10 Фудзисава Фармасьютикал Ко., Лтд. Стабилизированная фармацевтическая композиция в лиофилизированной форме
US20080161353A1 (en) * 2002-07-16 2008-07-03 Kevin Jeffrey Barnham 8-Hydroxy quinoline derivatives
WO2008087461A2 (en) * 2007-01-17 2008-07-24 Szegedi Tudományegyetem Use of kynurenic acid and derivatives thereof in the treatment of conditions of the gastrointestinal tract accompanied by hypermotility and inflammation or gout or multiple sclerosis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
БЕЛИКОВ В.Г. Фармацевтическая химия. М.: Высшая школа, 1993, с. 43-47. *

Also Published As

Publication number Publication date
PL3003298T3 (pl) 2024-07-15
US20160120857A1 (en) 2016-05-05
AU2014277568B2 (en) 2019-09-19
CA2914261A1 (en) 2014-12-11
JP6473938B2 (ja) 2019-02-27
WO2014194407A1 (en) 2014-12-11
JP2016521695A (ja) 2016-07-25
PH12015502717A1 (en) 2016-03-14
SG11201510003VA (en) 2016-01-28
RU2015156196A3 (enExample) 2018-05-24
RU2015156196A (ru) 2017-07-14
KR102294405B1 (ko) 2021-08-25
EP3003298A1 (en) 2016-04-13
NZ715579A (en) 2021-05-28
AU2014277568A1 (en) 2016-01-28
KR20160018676A (ko) 2016-02-17
ZA201600015B (en) 2019-07-31
EP3003298A4 (en) 2017-03-22
CA2914261C (en) 2020-02-11
PH12015502717B1 (en) 2023-09-13
US9737523B2 (en) 2017-08-22
DK3003298T3 (da) 2024-06-17
EP3003298B1 (en) 2024-03-20
BR112015030569A2 (pt) 2017-07-25
BR112015030569A8 (pt) 2020-01-07
ES2978920T3 (es) 2024-09-23

Similar Documents

Publication Publication Date Title
KR102294405B1 (ko) 항-섬유형성 화합물, 방법 및 이의 용도
Wu et al. Sinomenine contributes to the inhibition of the inflammatory response and the improvement of osteoarthritis in mouse-cartilage cells by acting on the Nrf2/HO-1 and NF-κB signaling pathways
JP5240586B2 (ja) 糖尿病性合併症治療用薬学的組成物
Chen et al. Lack of integrin α1β1 leads to severe glomerulosclerosis after glomerular injury
Tang et al. Piceatannol inhibits the IL-1β-induced inflammatory response in human osteoarthritic chondrocytes and ameliorates osteoarthritis in mice by activating Nrf2
He et al. Hydrogen sulfide regulates macrophage polarization and necroptosis to accelerate diabetic skin wound healing
Wang et al. Apelin attenuates TGF-β1-induced epithelial to mesenchymal transition via activation of PKC-ε in human renal tubular epithelial cells
WO2017100276A1 (en) Compositions and methods for treatment, amelioration, and prevention of diabetes-related skin ulcers
Liao et al. Critical role of the endogenous renin-angiotensin system in maintaining self-renewal and regeneration potential of epidermal stem cells
Xia et al. Inhibition of MRP4 alleviates sepsis-induced acute lung injury in rats
Liu et al. Enhanced migration of murine fibroblast-like 3T3-L1 preadipocytes on type I collagen-coated dish is reversed by silibinin treatment
Miao et al. Morin inhibits the transformation of fibroblasts towards myofibroblasts through regulating “PPAR-γ-glutaminolysis-DEPTOR” pathway in pulmonary fibrosis
Wei et al. TREM2-mediated macrophage glycolysis promotes skin wound angiogenesis via the Akt/mTOR/HIF-1α signaling axis
Gu et al. Protective effects of interleukin-22 on oxalate-induced crystalline renal injury via alleviating mitochondrial damage and inflammatory response
Riaz et al. Anti-hypertrophic effect of Na+/H+ exchanger-1 inhibition is mediated by reduced cathepsin B
Lee et al. Chondrocyte-derived extracellular matrix suppresses pathogenesis of human pterygium epithelial cells by blocking the NF-κB signaling pathways
Costantino et al. Losartan through Hsp70 Avoids Angiotensin II Induced Mesenchymal Epithelial Transition Proximal Tubule Cells from Spontaneously Hypertensive Rats
Chen et al. Renal denervation improves myocardial mitochondrial dysfunction and myocardial fibrosis by inhibiting the NE/KLF15/renalase pathway
Chen et al. Melatonin attenuates high-fat diet-and particulate matter-induced cardiac injury: involvement of mitochondrial quality and miR-221/222 expression
NZ715579B2 (en) Anti-fibrogenic compounds, methods and uses thereof
BR112015030569B1 (pt) Uso de compostos anti-fibrogênicos
TWI919263B (zh) 預防或治療骨關節炎的凝血調節素與ｍｉＲＮＡ
CN120437299A (zh) TrkA抑制剂在治疗肌腱粘连中的应用
Li et al. The role of TRPC6-mediated autophagy in myocardial ischaemia/reperfusion injury
Julovi et al. Involvement of Par-2 in the Induction of Matrix Metalloproteinase-2 by Activated Protein C in Cutaneous Wound Healing